Hong-Hoi Ting

NanoMab Technology Ltd. is a Chinese biopharmaceutical company that focuses on developing radiopharmaceuticals for cancer precision therapies. NanoMab Technology is based in Shanghai, CN and was founded in 2016 by Hong-Hoi Ting and Henry Ho. The private company aims to address the unmet medical needs of cancer patients worldwide by developing a pipeline of theranostics using its proprietary camelid antibody platform. NanoMab has filed an IMPD on NM-01 with the UK Medical Healthcare Products Regulatory Agency and is developing its radio-labelled NM-02 for clinical trials in both imaging and treatment of breast and gastric cancers. The company's third program, NM-03, is a single domain antibody targeting a pan-cancer marker and is in preclinical development as a theranostic.

Shanghai Full-Life Technologies Co. Ltd. is a Chinese company that focuses on radiopharmaceutical research and development, as well as production and commercialization. The private company's goal is to deliver clinical impact for patients.

Oxford Vacmedix UK Ltd. develops vaccines for the prevention of infectious diseases and cancer. The company was founded by Patrick Charles Morrish Baddeley in 2012 and is headquartered in Oxford, the United Kingdom.